MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Deschisă

3.97 2.85

Rezumat

Modificarea prețului

24h

Curent

Minim

3.82

Maxim

4.1

Indicatori cheie

By Trading Economics

Venit

44M

-26M

Vânzări

-5.8M

42M

Marjă de profit

-61.388

Angajați

550

EBITDA

44M

-22M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+7.87% upside

Dividende

By Dow Jones

Următoarele câștiguri

17 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

367M

1.4B

Deschiderea anterioară

1.12

Închiderea anterioară

3.97

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 ian. 2026, 19:05 UTC

Principalele dinamici ale pieței

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 ian. 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 ian. 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13 ian. 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 ian. 2026, 23:13 UTC

Achiziții, Fuziuni, Preluări

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 ian. 2026, 23:10 UTC

Achiziții, Fuziuni, Preluări

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 ian. 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 ian. 2026, 21:50 UTC

Achiziții, Fuziuni, Preluări

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 ian. 2026, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Basic Materials Roundup: Market Talk

13 ian. 2026, 21:20 UTC

Achiziții, Fuziuni, Preluări

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 ian. 2026, 21:20 UTC

Achiziții, Fuziuni, Preluări

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 ian. 2026, 21:20 UTC

Achiziții, Fuziuni, Preluări

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 ian. 2026, 21:15 UTC

Achiziții, Fuziuni, Preluări

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 ian. 2026, 21:08 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 ian. 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13 ian. 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 ian. 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 ian. 2026, 19:08 UTC

Achiziții, Fuziuni, Preluări

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 ian. 2026, 19:03 UTC

Câștiguri

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 ian. 2026, 18:50 UTC

Câștiguri

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 ian. 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 ian. 2026, 17:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Equities Roundup: Market Talk

13 ian. 2026, 17:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 ian. 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 ian. 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 ian. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13 ian. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13 ian. 2026, 17:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Basic Materials Roundup: Market Talk

13 ian. 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 ian. 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Comparație

Modificare preț

Maravai LifeSciences Holdings Inc (Class A) Așteptări

Obiectiv de preț

By TipRanks

7.87% sus

Prognoză pe 12 luni

Medie 4.25 USD  7.87%

Maxim 4.5 USD

Minim 4 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMaravai LifeSciences Holdings Inc (Class A) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

4 ratings

3

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

2.02 / 2.115Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

No Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat